Pfizer Inc. (PFE)

Pfizer is classed as a product business in the pharmaceutical preparations industry. Pfizer tags all its revenue as Biopharma, with $61.2 billion in fiscal 2025. By geography in fiscal 2025, the United States accounts for 59% of revenue, Developed Markets 26%, and Emerging Markets 15%. 35

Past

Pfizer's revenue grew from $42 billion in fiscal 2020 to $63 billion in fiscal 2025, up 8.5% a year, rising in 3 of 5 years; net income was positive in all 6 of those years. The deepest fall was 41% from fiscal 2022 to fiscal 2023. Over the past three fiscal years, the diluted share count shrank about 0.1% a year. Dividends declared per share rose from $1.22 in fiscal 2016 to $1.72 in fiscal 2025. Pfizer's filings since 2017 show no warning events: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice. 12

Present

In its latest annual figures on file, for the fiscal year ended 2025-12-31, Pfizer reported revenue of $63 billion and a profit of $7.8 billion. In fiscal 2025, Pfizer earned about 9 cents of profit for every dollar of shareholders' money; its products earned about 22 cents per dollar of everything the company owns; it owed about 58 cents per dollar of assets; and its share count grew 0.2% over the year. Pfizer's revenue of $63 billion in fiscal 2025 ranks in the top 1% by size among 315 names in its industry family; a net margin of 12.4% ranks in the top 16%; revenue growth of -14.8% a year over the last 3 filed years ranks in the bottom 23%. 31

The chief executive on the record is Bourla, Albert, filing under that title since 2019-01-02, 7.8 years; the 24 officers and directors filing in the last fifteen months have been on the record a median of 6.6 years; 6 officer or director changes were reported on Form 8-K since 2023-10-21, against the 24 people in charge now. 1

Future

A quarterly report (Form 10-Q) for the quarter ending 2026-09-30 is due by 2026-11-09 under the SEC's rules. An annual report (Form 10-K) for the fiscal year ending 2026-12-31 is due by 2027-03-01 under the SEC's rules. 4

Pfizer's cash of $1.1 billion against debt of $62 billion leaves -29.1% of its assets as net cash, in the bottom 4% of its family; cash from operations less capital spending is 14.5% of revenue (top 18%); a gross margin of 74.3% (top 43%); research spending of 16.7% of revenue (bottom 21%). Revenue grew -14.8% a year over the last three filed years against 8.5% over all 6, slowing; the newest year grew -1.6%; research spending grew -3% a year; capital spending grew -6.7% a year. 1

How the company operates

Pfizer is classed as a product business in the pharmaceutical preparations industry. Pfizer tags all its revenue as Biopharma, with $61.2 billion in fiscal 2025. By geography in fiscal 2025, the United States accounts for 59% of revenue, Developed Markets 26%, and Emerging Markets 15%. 35

New moves

On 2026-06-18, Pfizer filed a Form 8-K disclosing information to investors under Regulation FD. On 2026-06-18, Pfizer filed a Form 8-K reporting an officer or director change. On 2026-02-03, Pfizer filed a Form 8-K releasing results. On 2025-12-16, Pfizer filed a Form 8-K disclosing information to investors under Regulation FD. On 2025-11-21, Pfizer filed a Form 8-K reporting another event. 4